跳转至内容
Merck
CN

MAB3070

Anti-Granzyme B Antibody, clone GrB-7

culture supernatant, clone GrB-7, Chemicon®

别名:

Anti-Anti-CGL1, Anti-Anti-C11, Anti-Anti-CCPI, Anti-Anti-CGL-1, Anti-Anti-CSP-B, Anti-Anti-CSPB, Anti-Anti-CTLA1, Anti-Anti-CTSGL1, Anti-Anti-HLP, Anti-Anti-SECT

登录 查看组织和合同定价。

选择尺寸


关于此项目

UNSPSC Code:
12352203
NACRES:
NA.41
eCl@ss:
32160702
技术服务
需要帮助?我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助
技术服务
需要帮助?我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助

产品名称

Anti-Granzyme B Antibody, clone GrB-7, culture supernatant, clone GrB-7, Chemicon®

biological source

mouse

conjugate

unconjugated

antibody form

culture supernatant

antibody product type

primary antibodies

clone

GrB-7, monoclonal

species reactivity

human

manufacturer/tradename

Chemicon®

technique(s)

immunohistochemistry: suitable (paraffin)
western blot: suitable

isotype

IgG2a

NCBI accession no.

UniProt accession no.

shipped in

dry ice

target post-translational modification

unmodified

Quality Level

Gene Information

human ... GZMB(3002)

Application

Detect Granzyme B using this Anti-Granzyme B Antibody, clone GrB-7 validated for use in WB, IH(P).
Immunoblotting

Immunohistochemistry of granzyme B-expressing lymphocytes in sublimate sections and formalin-fixed paraffin-embedded tissues (1:20 dilution). Does not react with other cell types. Cannot be used on frozen sections.

Note on the use of MAB3070 on paraffin sections:

Tissue slides should be pretreated with an antigen retrieval method, such as treatment with 0.1M sodium citrate for 10 min at 100°C. A working dilution of 1:20 is advised, but optimal working dilutions must be determined by end user.
Research Category
Apoptosis & Cancer

Metabolism
Research Sub Category
Apoptosis - Additional

Enzymes & Biochemistry

Biochem/physiol Actions

Monoclonal antibody recognizes the 33 kDa granzyme B.

Reacts specifically with human serine protease granzyme B. Does not cross-react with human granzyme A. Granzyme B localizes in cytoplasmic granules and can be used as a marker for NK cells and activated cytotoxic T-cells.

Disclaimer

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

Physical form

Liquid

Preparation Note

Maintain at -20°C for up to 12 months.

Legal Information

CHEMICON is a registered trademark of Merck KGaA, Darmstadt, Germany

未找到合适的产品?  

试试我们的产品选型工具.

存储类别

10 - Combustible liquids

wgk

WGK 2


分析证书(COA)

输入产品批号来搜索 分析证书(COA) 。批号可以在产品标签上"批“ (Lot或Batch)字后找到。

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

Mingyao Meng et al.
The Journal of biological chemistry, 293(51), 19600-19612 (2018-10-20)
Several clinical immunotherapy trials with cytokine-induced killer (CIK) cells have been reported. However, molecular evidence of cell expansion, acquisition of tumor cytotoxicity, and safety of CIK cells is required before putting them to clinical use. Here, we performed dynamic transcriptomic
Milan Fiala et al.
Journal of neuroinflammation, 7, 76-76 (2010-11-11)
The contribution of inflammation to neurodegenerative diseases is increasingly recognized, but the role of inflammation in sporadic amyotrophic lateral sclerosis (sALS) is not well understood and no animal model is available. We used enzyme-linked immunosorbent assays (ELISAs) to measure the
Shintaro Yokoyama et al.
Clinical cancer research : an official journal of the American Association for Cancer Research, 22(18), 4727-4734 (2016-05-12)
The immune checkpoint of the programmed death 1/programmed death ligand 1 (PD-1/PD-L1) pathway is believed to play an important role in evasion of host antitumor immune surveillance in various malignancies; however, little is known about its role in thymic carcinoma.
Jenny Bulgarelli et al.
Frontiers in immunology, 10, 2353-2353 (2019-10-28)
Dendritic cell (DC)-based vaccination effectively induces anti-tumor immunity, although in the majority of cases this does not translate into a durable clinical response. However, DC vaccination is characterized by a robust safety profile, making this treatment a potential candidate for
Yong Zeng et al.
Molecular therapy. Methods & clinical development, 18, 422-427 (2020-07-23)
Intravitreal administration for human adeno-associated vector (AAV) delivery is easier and less traumatic to ocular tissues than subretinal injection, but it gives limited retinal transduction. AAV vectors are large (about 4,000 kDa) compared with most intraocular drugs, such as ranibizumab (48 kDa)

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系客户支持